Results 221 to 230 of about 5,283,585 (380)
A Novel Rat Model for Human Meibomian Gland Dysfunction and Ocular Rosacea. [PDF]
Zhu L +10 more
europepmc +1 more source
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
Right Ventricular Fibrosis With Pulmonary Arterial Hypertension. [PDF]
Li X +6 more
europepmc +1 more source
Uterus‐relaxing effect of β2‐agonists in combination with phosphodiesterase inhibitors: Studies on pregnant ratin vivoand on pregnant human myometriumin vitro [PDF]
Judit Verli +7 more
openalex +1 more source
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
The protective role of CD44 and microRNA-146a in tendinopathy. [PDF]
Hsu CC +6 more
europepmc +1 more source
Shuganjieyu capsule increases neurotrophic factor expression in a rat model of depression
Jingping Zhao +7 more
openalex +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source

